Setting

Global Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247653 | Pages: 187

Global oral antibiotics market will reach $26.67 billion by 2030, growing by 4.0% annually over 2020-2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure. Highlighted with 89 tables and 97 figures, this 187-page report “Global Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region. Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cephalosporin • Cefuroxime Axetil • Cephalexin • Cefixime • Cefpodoxime • Other Cephalosporin Penicillin Macrolides Tetracycline Quinolones Sulfonamides Aminoglycosides Other Drug Classes Based on Action Mechanism, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Urinary Tract Infections (UTIS) • Upper Respiratory Tract Infections (URTI) • Lower Respiratory Tract Infections (LRTIs) Dental Infections • Monotherapies • Combined Therapies Respiratory Tract Infections (RTIS) Other Applications Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • RoW (Saudi Arabia, UAE, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	10
1.1 Industry Definition and Research Scope	10
1.1.1 Industry Definition	10
1.1.2 Research Scope	11
1.2 Research Methodology	14
1.2.1 Overview of Market Research Methodology	14
1.2.2 Market Assumption	15
1.2.3 Secondary Data	15
1.2.4 Primary Data	15
1.2.5 Data Filtration and Model Design	17
1.2.6 Market Size/Share Estimation	18
1.2.7 Research Limitations	19
1.3 Executive Summary	20
2 Market Overview and Dynamics	23
2.1 Market Size and Forecast	23
2.1.1 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Global Market by Drug Class	41
3.1 Market Overview by Drug Class	41
3.2 Cephalosporin	43
3.3 Penicillin	45
3.4 Macrolides	46
3.5 Tetracycline	47
3.6 Quinolones	48
3.7 Sulfonamides	49
3.8 Aminoglycosides	50
3.9 Other Drug Classes	51
4 Segmentation of Global Market by Action Mechanism	52
4.1 Market Overview by Action Mechanism	52
4.2 Cell Wall Synthesis Inhibitors	54
4.3 Mycolic Acid Inhibitors	55
4.4 RNA Synthesis Inhibitors	56
4.5 DNA Synthesis Inhibitors	57
4.6 Protein Synthesis Inhibitors	58
4.7 Other Mechanisms	59
5 Segmentation of Global Market by Drug Origin	60
5.1 Market Overview by Drug Origin	60
5.2 Natural Antibiotics	62
5.3 Semi-synthetic Antibiotics	63
5.4 Synthetic Antibiotics	64
6 Segmentation of Global Market by Activity Spectrum	65
6.1 Market Overview by Activity Spectrum	65
6.2 Broad-spectrum Antibiotics	67
6.3 Narrow-spectrum Antibiotics	68
7 Segmentation of Global Market by Application	69
7.1 Market Overview by Application	69
7.2 Urinary Tract Infections (UTIS)	71
7.3 Dental Infections	72
7.3.1 Monotherapies for Dental Infections	73
7.3.2 Combined Therapies for Dental Infections	74
7.4 Respiratory Tract Infections (RTIS)	75
7.4.1 Upper Respiratory Tract Infections (URTI)	76
7.4.2 Lower Respiratory Tract Infections (LRTIs)	77
7.5 Other Applications	78
8 Segmentation of Global Market by Drug Type	79
8.1 Market Overview by Drug Type	79
8.2 Brand Antibiotics	81
8.3 Generic Antibiotics	82
9 Segmentation of Global Market by Region	83
9.1 Geographic Market Overview 2019-2030	83
9.2 North America Market 2019-2030 by Country	89
9.2.1 Overview of North America Market	89
9.2.2 U.S.	93
9.2.3 Canada	97
9.2.4 Mexico	99
9.3 European Market 2019-2030 by Country	101
9.3.1 Overview of European Market	101
9.3.2 Germany	105
9.3.3 UK	107
9.3.4 France	109
9.3.5 Spain	111
9.3.6 Italy	113
9.3.7 Russia	115
9.3.8 Rest of European Market	117
9.4 Asia-Pacific Market 2019-2030 by Country	119
9.4.1 Overview of Asia-Pacific Market	119
9.4.2 Japan	123
9.4.3 China	126
9.4.4 Australia	128
9.4.5 India	130
9.4.6 South Korea	132
9.4.7 Rest of APAC Region	134
9.5 South America Market 2019-2030 by Country	136
9.5.1 Argentina	139
9.5.2 Brazil	141
9.5.3 Chile	143
9.5.4 Rest of South America Market	145
9.6 MEA Market 2019-2030 by Country	146
9.6.1 UAE	149
9.6.2 Saudi Arabia	151
9.6.3 South Africa	153
9.6.4 Other National Markets	155
10 Competitive Landscape	156
10.1 Overview of Key Vendors	156
10.2 New Product Launch, Partnership, Investment, and M&A	160
10.3 Company Profiles	161
Abbott Laboratories	161
Astellas Pharma	163
AstraZeneca Plc	164
Bayer AG	165
Bristol Myers Squibb Company	166
Cipla Inc.	167
Dr. Reddy’s Laboratories Ltd.	168
Eli Lilly and Company	169
F. Hoffmann-La Roche Ltd.	170
Gilead Sciences, Inc.	171
GlaxoSmithKline plc.	172
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	173
Mayne Pharma Group Ltd.	174
MELINTA THERAPEUTICS, INC.	175
Merck KGaA	176
Novartis AG	177
Pfizer Inc.	178
Sanofi	179
Sun Pharmaceutical Industries Ltd.	180
11 Investing in Global Market: Risk Assessment and Management	181
11.1 Risk Evaluation of Global Market	181
11.2 Critical Success Factors (CSFs)	184
Related Reports and Products	187
List Of Tables

Table 1.  Snapshot of Global Oral Antibiotics Market, 2019-2030	21
Table 2.  Main Product Trends and Market Opportunities in Global Oral Antibiotics Market	33
Table 3. Global Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	41
Table 4. Global Oral Antibiotics Market: Cephalosporin by Molecule, 2019-2030, $ mn	44
Table 5. Global Oral Antibiotics Market by Action Mechanism, 2019-2030, $ mn	52
Table 6. Global Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	60
Table 7. Global Oral Antibiotics Market by Activity Spectrum, 2019-2030, $ mn	65
Table 8. Global Oral Antibiotics Market by Application, 2019-2030, $ mn	69
Table 9. Global Oral Antibiotics Market: Dental Infections by Type, 2019-2030, $ mn	72
Table 10. Global Oral Antibiotics Market: Respiratory Tract Infections (RTIS) by Type, 2019-2030, $ mn	75
Table 11. Global Oral Antibiotics Market by Drug Type, 2019-2030, $ bn	79
Table 12. Global Oral Antibiotics Market by Region, 2019-2030, $ bn	84
Table 13. Total Health Expenditure per capita in PPP International U.S. Dollars by Country	86
Table 14.  Leading National Oral Antibiotics Market, 2019 and 2030, $ bn	88
Table 15. North America Oral Antibiotics Market by Country, 2019-2030, $ bn	91
Table 16. U.S. Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	95
Table 17. U.S. Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	95
Table 18. U.S. Oral Antibiotics Market by Application, 2019-2030, $ mn	95
Table 19. Canada Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	98
Table 20. Canada Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	98
Table 21. Canada Oral Antibiotics Market by Application, 2019-2030, $ mn	98
Table 22. Mexico Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	100
Table 23. Mexico Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	100
Table 24. Mexico Oral Antibiotics Market by Application, 2019-2030, $ mn	100
Table 25. Europe Oral Antibiotics Market by Country, 2019-2030, $ bn	104
Table 26. Germany Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	106
Table 27. Germany Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	106
Table 28. Germany Oral Antibiotics Market by Application, 2019-2030, $ mn	106
Table 29. UK Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	108
Table 30. UK Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	108
Table 31. UK Oral Antibiotics Market by Application, 2019-2030, $ mn	108
Table 32. France Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	110
Table 33. France Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	110
Table 34. France Oral Antibiotics Market by Application, 2019-2030, $ mn	110
Table 35. Spain Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	112
Table 36. Spain Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	112
Table 37. Spain Oral Antibiotics Market by Application, 2019-2030, $ mn	112
Table 38. Italy Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	114
Table 39. Italy Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	114
Table 40. Italy Oral Antibiotics Market by Application, 2019-2030, $ mn	114
Table 41. Russia Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	116
Table 42. Russia Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	116
Table 43. Russia Oral Antibiotics Market by Application, 2019-2030, $ mn	116
Table 44. Oral Antibiotics Market in Rest of Europe by Country, 2019-2030, $ bn	118
Table 45. APAC Oral Antibiotics Market by Country, 2019-2030, $ bn	121
Table 46. Japan Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	125
Table 47. Japan Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	125
Table 48. Japan Oral Antibiotics Market by Application, 2019-2030, $ mn	125
Table 49. China Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	127
Table 50. China Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	127
Table 51. China Oral Antibiotics Market by Application, 2019-2030, $ mn	127
Table 52. Australia Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	129
Table 53. Australia Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	129
Table 54. Australia Oral Antibiotics Market by Application, 2019-2030, $ mn	129
Table 55. India Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	131
Table 56. India Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	131
Table 57. India Oral Antibiotics Market by Application, 2019-2030, $ mn	131
Table 58. South Korea Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	133
Table 59. South Korea Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	133
Table 60. South Korea Oral Antibiotics Market by Application, 2019-2030, $ mn	133
Table 61. Oral Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn	135
Table 62. South America Oral Antibiotics Market by Country, 2019-2030, $ bn	138
Table 63. Argentina Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	140
Table 64. Argentina Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	140
Table 65. Argentina Oral Antibiotics Market by Application, 2019-2030, $ mn	140
Table 66. Brazil Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	142
Table 67. Brazil Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	142
Table 68. Brazil Oral Antibiotics Market by Application, 2019-2030, $ mn	142
Table 69. Chile Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	144
Table 70. Chile Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	144
Table 71. Chile Oral Antibiotics Market by Application, 2019-2030, $ mn	144
Table 72. MEA Oral Antibiotics Market by Country, 2019-2030, $ bn	148
Table 73. UAE Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	150
Table 74. UAE Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	150
Table 75. UAE Oral Antibiotics Market by Application, 2019-2030, $ mn	150
Table 76. Saudi Arabia Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	152
Table 77. Saudi Arabia Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	152
Table 78. Saudi Arabia Oral Antibiotics Market by Application, 2019-2030, $ mn	152
Table 79. South Africa Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	154
Table 80. South Africa Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	154
Table 81. South Africa Oral Antibiotics Market by Application, 2019-2030, $ mn	154
Table 82. Breakdown of Global Market by Key Vendor, 2019, %	158
Table 83. Abbott Laboratories: Company Snapshot	161
Table 84. Abbott Laboratories: Business Segmentation	161
Table 85. Abbott Laboratories: Product Portfolio	162
Table 86. Abbott Laboratories: Revenue, 2016-2018, $ mn	162
Table 87. Abbott Laboratories: Recent Developments	162
Table 88.  Risk Evaluation for Investing in Global Market, 2019-2030	182
Table 89. Critical Success Factors and Key Takeaways	185
List Of Figures

Figure 1. Research Method Flow Chart	14
Figure 2. Breakdown of Primary Research	16
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	18
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	20
Figure 5. Global Oral Antibiotics Market, 2019-2030, $ mn	23
Figure 6. Impact of COVID-19 on Business	24
Figure 7. Primary Drivers and Impact Factors of Global Oral Antibiotics Market	26
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	29
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	29
Figure 10. Primary Restraints and Impact Factors of Global Oral Antibiotics Market	30
Figure 11. Investment Opportunity Analysis	34
Figure 12. Porter’s Fiver Forces Analysis of Global Oral Antibiotics Market	37
Figure 13. Breakdown of Global Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue	42
Figure 14. Global Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)	42
Figure 15. Global Oral Antibiotics Market: Cephalosporin, 2019-2030, $ mn	43
Figure 16. Global Oral Antibiotics Market: Penicillin, 2019-2030, $ mn	45
Figure 17. Global Oral Antibiotics Market: Macrolides, 2019-2030, $ mn	46
Figure 18. Global Oral Antibiotics Market: Tetracycline, 2019-2030, $ mn	47
Figure 19. Global Oral Antibiotics Market: Quinolones, 2019-2030, $ mn	48
Figure 20. Global Oral Antibiotics Market: Sulfonamides, 2019-2030, $ mn	49
Figure 21. Global Oral Antibiotics Market: Aminoglycosides, 2019-2030, $ mn	50
Figure 22. Global Oral Antibiotics Market: Other Drug Classes, 2019-2030, $ mn	51
Figure 23. Breakdown of Global Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue	53
Figure 24. Global Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)	53
Figure 25. Global Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn	54
Figure 26. Global Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn	55
Figure 27. Global Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn	56
Figure 28. Global Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn	57
Figure 29. Global Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn	58
Figure 30. Global Oral Antibiotics Market: Other Mechanisms, 2019-2030, $ mn	59
Figure 31. Breakdown of Global Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue	61
Figure 32. Global Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)	61
Figure 33. Global Oral Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn	62
Figure 34. Global Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn	63
Figure 35. Global Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn	64
Figure 36. Breakdown of Global Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue	66
Figure 37. Global Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)	66
Figure 38. Global Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn	67
Figure 39. Global Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn	68
Figure 40. Breakdown of Global Oral Antibiotics Market by Application, 2019-2030, % of Revenue	70
Figure 41. Global Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	70
Figure 42. Global Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, $ mn	71
Figure 43. Global Oral Antibiotics Market: Dental Infections, 2019-2030, $ mn	72
Figure 44. Global Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, $ mn	73
Figure 45. Global Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, $ mn	74
Figure 46. Global Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, $ mn	75
Figure 47. Global Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, $ mn	76
Figure 48. Global Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, $ mn	77
Figure 49. Global Oral Antibiotics Market: Other Applications, 2019-2030, $ mn	78
Figure 50. Breakdown of Global Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue	79
Figure 51. Global Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)	80
Figure 52. Global Oral Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn	81
Figure 53. Global Oral Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn	82
Figure 54.  Global Market Snapshot by Region	83
Figure 55.  Geographic Spread of Worldwide Oral Antibiotics Market, 2019-2030, % of Sales Revenue	84
Figure 56. Global Addressable Market Cap in 2020-2030 by Region, Value ($ bn) and Share (%)	85
Figure 57. Health Spending as a Share of GDP by Country, 2015 and 2030	87
Figure 58.  North American Oral Antibiotics Market, 2019-2030, $ bn	90
Figure 59. Breakdown of North America Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	91
Figure 60. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	92
Figure 61. U.S. Oral Antibiotics Market, 2019-2030, $ bn	94
Figure 62. Rising Incidence of Infectious Disease in U.S.	94
Figure 63. Canada Oral Antibiotics Market, 2019-2030, $ bn	97
Figure 64.  Oral Antibiotics Market in Mexico, 2015-2030, $ bn	99
Figure 65.  European Oral Antibiotics Market, 2019-2030, $ bn	102
Figure 66. Breakdown of European Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	103
Figure 67. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	104
Figure 68.  Oral Antibiotics Market in Germany, 2019-2030, $ bn	105
Figure 69.  Oral Antibiotics Market in UK, 2019-2030, $ bn	107
Figure 70.  Oral Antibiotics Market in France, 2019-2030, $ bn	109
Figure 71.  Oral Antibiotics Market in Spain, 2019-2030, $ bn	111
Figure 72.  Oral Antibiotics Market in Italy, 2019-2030, $ bn	113
Figure 73.  Oral Antibiotics Market in Russia, 2019-2030, $ bn	115
Figure 74.  Oral Antibiotics Market in Rest of Europe, 2019-2030, $ bn	117
Figure 75. Asia-Pacific Oral Antibiotics Market, 2019-2030, $ bn	120
Figure 76. Breakdown of APAC Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	120
Figure 77. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	122
Figure 78.  Oral Antibiotics Market in Japan, 2019-2030, $ bn	124
Figure 79.  Oral Antibiotics Market in China, 2019-2030, $ bn	126
Figure 80.  Oral Antibiotics Market in Australia, 2019-2030, $ bn	128
Figure 81.  Oral Antibiotics Market in India, 2019-2030, $ bn	130
Figure 82.  Oral Antibiotics Market in South Korea, 2019-2030, $ bn	132
Figure 83.  Oral Antibiotics Market in Rest of APAC, 2019-2030, $ bn	134
Figure 84. South America Oral Antibiotics Market, 2019-2030, $ bn	137
Figure 85. Breakdown of South America Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	137
Figure 86. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	138
Figure 87.  Oral Antibiotics Market in Argentina, 2019-2030, $ bn	139
Figure 88.  Oral Antibiotics Market in Brazil, 2019-2030, $ bn	141
Figure 89.  Oral Antibiotics Market in Chile, 2019-2030, $ bn	143
Figure 90.  Oral Antibiotics Market in Rest of South America, 2019-2030, $ bn	145
Figure 91. Oral Antibiotics Market in Middle East and Africa (MEA), 2019-2030, $ bn	147
Figure 92. Breakdown of MEA Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	147
Figure 93. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	148
Figure 94.  Oral Antibiotics Market in UAE, 2019-2030, $ bn	149
Figure 95.  Oral Antibiotics Market in Saudi Arabia, 2019-2030, $ bn	151
Figure 96.  Oral Antibiotics Market in South Africa, 2019-2030, $ bn	153
Figure 97. Growth Stage of Global Oral Antibiotics Industry over the Forecast Period	156
Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories	
Astellas Pharma	
AstraZeneca Plc	
Bayer AG	
Bristol Myers Squibb Company	
Cipla Inc.	
Dr. Reddy’s Laboratories Ltd.	
Eli Lilly and Company	
F. Hoffmann-La Roche Ltd.	
Gilead Sciences, Inc.	
GlaxoSmithKline plc.	
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	
Mayne Pharma Group Ltd.	
MELINTA THERAPEUTICS, INC.	
Merck KGaA	
Novartis AG	
Pfizer Inc.	
Sanofi	
Sun Pharmaceutical Industries Ltd.